Post-earnings recap
Reported
Thu, May 1, 2014
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a larger-than-expected loss per share, which contributed to a 2.4% decline in stock price. Investors may be concerned about the lack of revenue figures and guidance, indicating uncertainty about the company's near-term performance. The focus on clinical programs suggests that the company is prioritizing long-term growth over immediate financial results.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.33 | N/A | -27.91% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook, emphasizing the importance of ongoing clinical trials. They did not offer any specific guidance for future performance.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its clinical programs.